GNI Group Reshapes Top Management as Gyre Advances Cullgen Acquisition

GNI Group ( (JP:2160) ) has shared an announcement.

GNI Group has strengthened its management structure as Gyre Therapeutics, a consolidated subsidiary, advances the acquisition of Cullgen, with Gyre having filed a related report with the U.S. Securities and Exchange Commission. In tandem with this transaction, GNI’s President and CEO, Dr. Ying Luo, has assumed the additional role of CEO at Gyre and Chairman at Cullgen, while retaining his existing duties at GNI.

To support this broader remit and accelerate the group’s global growth strategy, GNI has additionally appointed Director and Executive Vice President Ryosuke Matsui as a Representative Executive Officer, COO and CFO, effective May 6, 2026. The reshuffle also confirms Ping Zhang as Chairman of Gyre, replacing his prior interim CEO role, underscoring a move toward a more agile and robust governance framework as GNI intensifies its push to become a fully fledged global pharmaceutical group.

The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3800.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

More about GNI Group

GNI Group Ltd. is a Japan-based biopharmaceutical company listed on the TSE Growth market under security code 2160. The group focuses on developing and commercializing pharmaceutical products globally, and is pursuing a growth strategy aimed at transforming itself into a “Global Pharma” player through its consolidated subsidiaries, including U.S.-based Gyre Therapeutics, Inc. and Cullgen Inc.

Average Trading Volume: 1,346,208

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen168.4B

See more data about 2160 stock on TipRanks’ Stock Analysis page.